-- 四川科倫製薬（SHE:002422）の帰属利益は、第1四半期に前年同期の5億8420万元から22%減の4億5370万元となった。これは、同社が水曜日に深セン証券取引所に提出した書類で明らかになった。 同社の1株当たり利益は、前年同期の0.37元から22%減の0.29元となった。 営業収益は、前年同期の43億9000万元から3%減の42億6000万元となった。
Related Articles
Treasury
Brief: Bank of Canada Governor Macklem's Press Conference on Policy Decision, MPR Starts
$^GSPTSE$.GSPTSE$$CXY
Sectors
US Total Weekly EIA Crude Oil Stocks Fall by 13.4 Million Barrels After Prior 2.2 Million Decrease
Research
Research Alert: Etsy: Solid Q1 As Etsy Marketplace Gms Growth Accelerates
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ETSY delivered encouraging Q1 2026 results, with revenue of $631M beating the $617M consensus and adj-EBITDA of $185M beating $177M consensus. Etsy marketplace GMS returned to solid 5.5% Y/Y growth, marking a 540 bps improvement from Q4 2025 and the second consecutive quarter of expansion after years of decline. We believe this represents a potential inflection point led by mobile app improvements (personalization and search functions are getting better), with GMS growth accelerating to 11.2% Y/Y. For Q2 2026, ETSY guides for the third consecutive quarter of GMS growth of 3%-5% and full-year low-single digit GMS growth. We're encouraged by improving buyer metrics with active buyers at 86.6M (first sequential growth in two years) and GMS per buyer up 1.8% Y/Y. Take rate expanded 180 bps Y/Y to 25.7% while adj-EBITDA margins improved 100 bps Y/Y to 29.3%. We believe ETSY's strategic transformation is gaining traction but acknowledge an uncertain macro backdrop given the current geopolitical environment.
$ETSY